Viewing Study NCT03086395


Ignite Creation Date: 2025-12-24 @ 1:33 PM
Ignite Modification Date: 2026-01-07 @ 7:00 AM
Study NCT ID: NCT03086395
Status: WITHDRAWN
Last Update Posted: 2017-03-22
First Post: 2017-03-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)
Sponsor: Case Comprehensive Cancer Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module